By Stephen Nakrosis
Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.
In the Thursday late trading session, the company's shares were at $10.62, with volume topping 1.2 million shares. The stock gained 3.7% in the day's regular session, closing at $4.71.
Portage said the data showed both single agent activity for PORT-7, and a dramatic inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma.
The company said, to their knowledge, their's was the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage added it is making preparations to commence a first-in-human clinical trial with PORT-7.
Portage also said it is advancing the dose escalation of PORT-6, an A2A adenosine receptor.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 27, 2025 18:02 ET (22:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。